US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025

"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights:

US Breast Cancer Drug Market Opportunity: US$ 20 Billion
US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment
US Breast Cancer Marketed Drugs: 42 Drugs
US Breast Cancer Drug Clinical Pipeline: 317 Drugs
Dosage and Pricing Insight for Preventive and Treatment Drugs
US Breast Cancer Drug Market Dynamics

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-us-breast-cancer-drug-market,-price,-dosage-and-clinical-pipeline-insight-2025.php

Report Table of Contents

1. US - Cancer Incidence and Prevalence

2. US Breast Cancer Market Landscape
2.1 Incidence and Prevalence
2.2 Diagnosis of Breast Cancer

3. US Breast Cancer Drug Market
3.1 Overview US Breast Cancer Drug Market
3.2 Diagnosis and Screening Market Scenario
3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)

4. Forward Looking Developments in Breast Cancer Drug Market
4.1 ER Positive Breast Cancer
4.1.1 CDK4/6 Inhibitors
4.1.2 PI3K Inhibitors
4.1.3 Crizotinib for Lobular Breast Cancer
4.2 HER2-Positive Breast Cancer
4.2.1 Palbociclib and Herceptin (Spain)
4.2.2 Tecentriq - FDA Approval for Breast Cancer
4.3 Triple Negative Breast Cancer
4.3.1 Atezolizumab and Nab-Paclitaxel
4.3.2 Sacituzumab Govitecan
4.3.3 Carboplatin and Docetaxel

5. US - Dosage and Pricing Insight for Drugs Approved for the Prevention of Breast Cancer
5.1 Raloxifene Hydrochloride
5.2 Elvista
5.3 Tamoxifen Citrate

6. US - Dosage and Pricing Insight for Drugs Approved for the Treatment of Breast Cancer
6.1 Abemaciclib
6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
6.3 Ado-Trastuzumab Emtansine
6.4 Afinitor (Everolimus)
6.5 Anastrozole
6.6 Aromasin (Exemestane)
6.7 Xeloda (Capecitabine)
6.8 Docetaxel (Docetaxel Anhydrous)
6.9 Doxorubicin Hydrochloride
6.10 Ellence (Epirubicin Hydrochloride)
6.11 Fluorouracil
6.12 Taxol (Paclitaxel)
6.13 Methotrexate
6.14 Cyclophosphamide
7. US Breast Cancer Drug Market Dynamics
7.1 Market Drivers
7.1.1 Increasing Incidence of Breast Cancer
7.1.2 Research and Development for Novel Drugs
7.1.3 Increase in Healthcare Expenditure and Funding
7.1.4 Increasing Breast Cancer Screening Programs
7.1.5 Rising Consumption of Tobacco and Alcohol
7.2 US Breast Cancer Drug Market Challenges
7.2.1 Pricing Pressure Experienced by the Innovators
7.2.2 High Cost associated with Drug Development and Clinical Trials
7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US - Breast Cancer Drug Market Forecast
8.1 Future Potential of US Breast Cancer Drug Market
8.2 Opportunities for Forthcoming Drug Classes

9. US - Breast Cancer Drug Clinical Pipeline by Company and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
9.10 Registered

10. US - Marketed Breast Cancer Drug Clinical Insight by Company
10.1 Afinitor
10.2 LYNPARZA
10.3 Abraxane
10.4 Verzenio
10.5 Kisqali
10.6 Lymphoseek
10.7 Kadcyla
10.8 Ibrance
10.9 Nerlynx
10.10 Soltamox
10.11 Tykerb
10.12 Zoladex
10.13 Omnitarg, Perjeta
10.14 Halaven
10.15 Taxotere
10.16 Other( 27 Drugs Profiles)

11. Competitive Landscape
11.1 Agilent Technologies
11.2 AstraZeneca
11.3 Bayer HealthCare Pharmaceuticals
11.4 Bristol-Myers Squibb
11.5 Eisai Co Ltd
11.6 Eli Lilly
11.7 Novartis
11.8 Onyx Pharmaceuticals
11.9 Orion
11.10 Perrigo
11.11 Pfizer
11.12 Roche

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.